G. Roane

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

R. Collins, C. Gordon, D. Isenberg, 2016, Arthritis & rheumatology.

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

R. Marcus, D. Furst, K. Dao, 2019, Arthritis Care & Research.

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

G. Burmester, P. Leszczyński, M. Bao, 2013, Annals of the rheumatic diseases.

Scleroderma: A Review of Vascular Features

E. Leroy, G. Roane, 1995 .

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

G. Burmester, P. Leszczyński, M. Bao, 2014, Annals of the rheumatic diseases.

SAT0105 Summacta: A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy Of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Dmards in Patients With Moderate to Severe Ra

G. Burmester, P. Leszczyński, A. Cantagrel, 2013 .

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

D. Furst, K. Dao, M. Rosen, 2019, Arthritis care & research.